Privately Held Alvogen Announces Favorable Ruling on Patents Related to the Company’s Proposed Generic to Xifaxan® for IBS-D
Alvogen announced a significant district court ruling in favor of its proposed generic version of Xifaxan®, a treatment for irritable bowel syndrome with diarrhea (IBS-D).
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
“We are extremely pleased with the district court’s decision, which brings us one step closer to bringing a more affordable alternative to patients taking Xifaxan for IBS-D,” said
About Alvogen
Alvogen is a privately held pharmaceutical company focused on developing, manufacturing and selling generic and branded products for the US market. The company has a diverse portfolio and pipeline that includes both branded and generic products across various dosage forms. The Alvogen-family of companies and include Alvogen US (Generics), Almatica (Brands) and Almaject (Injectables).
View source version on businesswire.com: https://www.businesswire.com/news/home/20220811005336/en/
Elisabet.Hjaltadottir@alvogen.com
Source: Alvogen